R
Ruth Pettengell
Researcher at St George's, University of London
Publications - 161
Citations - 10680
Ruth Pettengell is an academic researcher from St George's, University of London. The author has contributed to research in topics: Rituximab & Febrile neutropenia. The author has an hindex of 42, co-authored 160 publications receiving 9542 citations. Previous affiliations of Ruth Pettengell include St George's Hospital.
Papers
More filters
Journal ArticleDOI
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh,Lorenz Trümper,Anders Österborg,Ruth Pettengell,Marek Trneny,Kevin Imrie,David D.F. Ma,Devinder Gill,Jan Walewski,Pier Luigi Zinzani,Rolf A. Stahel,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Tuula Lehtinen,Armando López-Guillermo,Claudia Corrado,Adriana Scheliga,Noel Milpied,Myriam Mendila,Michelle Rashford,Evelyn Kuhnt,Markus Loeffler +23 more
TL;DR: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows for a more refined therapeutic approach for these patients.
Journal ArticleDOI
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
Matti Aapro,Julia Bohlius,David Cameron,Lissandra Dal Lago,J. Peter Donnelly,Nora Kearney,Gary H. Lyman,Ruth Pettengell,Vivianne C. G. Tjan-Heijnen,Jan Walewski,Damien C. Weber,Christoph C. Zielinski +11 more
TL;DR: Clinical evidence shows that filgrastim, lenograstim and pegfilgrastIM have clinical efficacy and the use of any of these agents to prevent FN and FN-related complications where indicated and prophylactic G-CSF support is recommended.
Journal ArticleDOI
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Lennard Y W Lee,Jean-Baptiste Cazier,Vasileios Angelis,Roland Arnold,Vartika Bisht,Naomi A. Campton,Julia Chackathayil,Vinton Cheng,Helen Curley,Matthew W. Fittall,Luke Freeman-Mills,Spyridon Gennatas,Anshita Goel,Simon Hartley,D.J. Hughes,David J. Kerr,Alvin J.X. Lee,Rebecca Lee,Sophie McGrath,Christopher P. Middleton,N. Murugaesu,Thomas Newsom-Davis,Alicia Okines,Anna Olsson-Brown,Claire Palles,Yi Pan,Ruth Pettengell,Thomas Powles,Emily A. Protheroe,Karin Purshouse,Archana Sharma-Oates,Shivan Sivakumar,Ashley J. Smith,Thomas Starkey,Chris D. Turnbull,Csilla Várnai,Nadia Yousaf,Rachel Kerr,Gary Middleton +38 more
TL;DR: The clinical and demographic characteristics and COVID-19 outcomes in patients with cancer appear to be principally driven by age, gender, and comorbidities.
Journal ArticleDOI
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Michael Pfreundschuh,Evelyn Kuhnt,Lorenz Trümper,Anders Österborg,Marek Trneny,Lois E. Shepherd,Devinder Gill,Jan Walewski,Ruth Pettengell,Ulrich Jaeger,Pier Luigi Zinzani,Ofer Shpilberg,Stein Kvaløy,Peter de Nully Brown,Rolf A. Stahel,Noel Milpied,Armando López-Guillermo,Viola Poeschel,Sandra Grass,Markus Loeffler,Niels Murawski +20 more
TL;DR: Rituximab added to six cycles of CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis diffuse large-B-cell lymphoma and the definition of two prognostic subgroups allows a more refined therapeutic approach to these patients than does assessment by IPI alone.
Journal ArticleDOI
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
Matti Aapro,David Cameron,Ruth Pettengell,Julia Bohlius,Jeffrey Crawford,Michael Ellis,Nora Kearney,Gary H. Lyman,Vivianne C.G. Tjan-Heijnen,Jan Walewski,Damien C. Weber,Christoph C. Zielinski +11 more
TL;DR: Recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced neutropenia are formulated and it is recommended that patient-related adverse risk factors such as elderly age, be evaluated in the overall assessment of FN risk prior to administering each cycle of chemotherapy.